Cellectis Sa Stock Buy Hold or Sell Recommendation
| CLLS Stock | USD 2.50 0.12 4.58% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Cellectis SA is 'Strong Sell'. Macroaxis provides Cellectis buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CLLS positions. The advice algorithm takes into account all of Cellectis' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Cellectis' buy or sell advice are summarized below:
Real Value 2.26 | Target Price 7.5 | Hype Value 2.62 | Market Value 2.5 | Naive Value 2.48 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Cellectis SA given historical horizon and risk tolerance towards Cellectis. When Macroaxis issues a 'buy' or 'sell' recommendation for Cellectis SA, the advice is generated through an automated system that utilizes algorithms and statistical models.
Cellectis |
Execute Cellectis Buy or Sell Advice
The Cellectis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cellectis SA. Macroaxis does not own or have any residual interests in Cellectis SA or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cellectis' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Cellectis Trading Alerts and Improvement Suggestions
| Cellectis SA generated a negative expected return over the last 90 days | |
| Cellectis SA has high historical volatility and very poor performance | |
| Cellectis SA has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 16.5 M. Net Loss for the year was (85.01 M) with profit before overhead, payroll, taxes, and interest of 23.95 M. | |
| Cellectis SA currently holds about 153.13 M in cash with (65.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from benzinga.com: Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs |
Cellectis current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cellectis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cellectis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Cellectis Returns Distribution Density
The distribution of Cellectis' historical returns is an attempt to chart the uncertainty of Cellectis' future price movements. The chart of the probability distribution of Cellectis daily returns describes the distribution of returns around its average expected value. We use Cellectis SA price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cellectis returns is essential to provide solid investment advice for Cellectis.
| Mean Return | 0.01 | Value At Risk | -5.54 | Potential Upside | 5.28 | Standard Deviation | 3.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cellectis historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cellectis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cellectis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cellectis SA backward and forwards among themselves. Cellectis' institutional investor refers to the entity that pools money to purchase Cellectis' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2023-09-30 | 47.2 K | Citadel Advisors Llc | 2023-09-30 | 34.3 K | Susquehanna International Group, Llp | 2023-12-31 | 19.5 K | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 15.8 K | Wells Fargo & Co | 2023-12-31 | 14.3 K | Geode Capital Management, Llc | 2023-12-31 | 10.8 K | Advisor Group Holdings, Inc. | 2023-12-31 | 4.6 K | Qube Research & Technologies | 2023-12-31 | 4.5 K | Rhumbline Advisers | 2023-12-31 | 3.9 K | Long Focus Capital Management, Llc | 2023-12-31 | 4.5 M | Capital Research & Mgmt Co - Division 3 | 2023-12-31 | 1.8 M |
Cellectis Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (111.0M) | (99.4M) | (55.5M) | (92.4M) | (31.5M) | (29.9M) | |
| Free Cash Flow | (82.1M) | (126.5M) | (124.3M) | (89.9M) | (66.7M) | (70.1M) | |
| Depreciation | 6.9M | 9.8M | 16.6M | 18.4M | 18.1M | 9.6M | |
| Other Non Cash Items | (8.3M) | 12.0M | (5.6M) | (7.6M) | 5.2M | 5.5M | |
| Capital Expenditures | 13.0M | 46.3M | 19.7M | 2.4M | 1.1M | 1.0M | |
| Net Income | (115.2M) | (97.5M) | (125.1M) | (98.7M) | (85.0M) | (89.3M) | |
| End Period Cash Flow | 340.5M | 241.1M | 185.6M | 93.2M | 66.2M | 62.9M | |
| Change To Inventory | (2.6M) | 1.3M | 1.6M | 1.7M | 1.9M | 2.0M | |
| Investments | (35.9M) | (54.3M) | 27.0M | (2.8M) | (2.0M) | (2.1M) | |
| Net Borrowings | (3.4M) | 17.6M | (12.5M) | (6.6M) | (5.9M) | (5.6M) | |
| Change To Netincome | 14.4M | 12.8M | (2.8M) | 6.0M | 5.4M | 5.1M |
Cellectis Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cellectis or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cellectis' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cellectis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.17 | |
β | Beta against NYSE Composite | 2.06 | |
σ | Overall volatility | 3.25 | |
Ir | Information ratio | -0.03 |
Cellectis Volatility Alert
Cellectis SA shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cellectis' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cellectis' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cellectis Fundamentals Vs Peers
Comparing Cellectis' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cellectis' direct or indirect competition across all of the common fundamentals between Cellectis and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cellectis or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cellectis' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cellectis to competition |
| Fundamentals | Cellectis | Peer Average |
| Return On Equity | -0.71 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Operating Margin | (12.57) % | (5.51) % |
| Current Valuation | 161.78 M | 16.62 B |
| Shares Outstanding | 71.95 M | 571.82 M |
| Shares Owned By Insiders | 12.10 % | 10.09 % |
| Shares Owned By Institutions | 18.82 % | 39.21 % |
| Number Of Shares Shorted | 676.48 K | 4.71 M |
| Price To Earning | (14.84) X | 28.72 X |
| Price To Book | 2.53 X | 9.51 X |
| Price To Sales | 8.29 X | 11.42 X |
| Revenue | 16.5 M | 9.43 B |
| Gross Profit | 23.95 M | 27.38 B |
| EBITDA | (62.82 M) | 3.9 B |
| Net Income | (85.01 M) | 570.98 M |
| Cash And Equivalents | 153.13 M | 2.7 B |
| Cash Per Share | 3.37 X | 5.01 X |
| Total Debt | 82.85 M | 5.32 B |
| Debt To Equity | 0.52 % | 48.70 % |
| Current Ratio | 3.17 X | 2.16 X |
| Book Value Per Share | 1.37 X | 1.93 K |
| Cash Flow From Operations | (65.68 M) | 971.22 M |
| Short Ratio | 19.61 X | 4.00 X |
| Earnings Per Share | (1.41) X | 3.12 X |
| Target Price | 7.43 | |
| Number Of Employees | 231 | 18.84 K |
| Beta | 3.13 | -0.15 |
| Market Capitalization | 178.44 M | 19.03 B |
| Total Asset | 261.22 M | 29.47 B |
| Retained Earnings | (439.5 M) | 9.33 B |
| Working Capital | 80.82 M | 1.48 B |
| Current Asset | 51 M | 9.34 B |
| Current Liabilities | 26.28 M | 7.9 B |
Cellectis Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cellectis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cellectis Buy or Sell Advice
When is the right time to buy or sell Cellectis SA? Buying financial instruments such as Cellectis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 14.6M | 28.5M | 32.8M | 34.4M | Total Assets | 382.1M | 261.2M | 300.4M | 264.8M |
Use Investing Ideas to Build Portfolios
In addition to having Cellectis in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials Thematic Idea Now
Financials
Companies that provide financial services to business or retail customers. The Financials theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cellectis Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Cellectis Stock analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Cellectis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectis. If investors know Cellectis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Revenue Per Share 0.471 | Quarterly Revenue Growth (0.12) | Return On Assets (0.19) | Return On Equity (0.71) |
The market value of Cellectis SA is measured differently than its book value, which is the value of Cellectis that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectis' value that differs from its market value or its book value, called intrinsic value, which is Cellectis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectis' market value can be influenced by many factors that don't directly affect Cellectis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.